Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Christopher A. Klebanoff, Luca Gattinoni, Parizad Torabi-Parizi, Keith Kerstann, Adela R. Cardones, Steven E. Finkelstein, Douglas C. Palmer, Paul A. Antony, Samuel T Hwang, Steven A. Rosenberg, Thomas A. Waldmann, Nicholas P. Restifo

Research output: Contribution to journalArticle

553 Citations (Scopus)

Abstract

Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.

Original languageEnglish (US)
Pages (from-to)9571-9576
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number27
DOIs
StatePublished - Jul 5 2005
Externally publishedYes

Fingerprint

Immunity
T-Lymphocytes
Lymphoid Tissue
Neoplasms
Neoplasm Antigens
Interleukin-2
Vaccination
Adoptive Immunotherapy
Interleukin-15
T-Lymphocyte Subsets
Microarray Analysis
Transcriptome
Therapeutics
Infection
Population
Genes

Keywords

  • Homing
  • IL-15
  • IL-2
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • General

Cite this

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. / Klebanoff, Christopher A.; Gattinoni, Luca; Torabi-Parizi, Parizad; Kerstann, Keith; Cardones, Adela R.; Finkelstein, Steven E.; Palmer, Douglas C.; Antony, Paul A.; Hwang, Samuel T; Rosenberg, Steven A.; Waldmann, Thomas A.; Restifo, Nicholas P.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 27, 05.07.2005, p. 9571-9576.

Research output: Contribution to journalArticle

Klebanoff, CA, Gattinoni, L, Torabi-Parizi, P, Kerstann, K, Cardones, AR, Finkelstein, SE, Palmer, DC, Antony, PA, Hwang, ST, Rosenberg, SA, Waldmann, TA & Restifo, NP 2005, 'Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells', Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9571-9576. https://doi.org/10.1073/pnas.0503726102
Klebanoff, Christopher A. ; Gattinoni, Luca ; Torabi-Parizi, Parizad ; Kerstann, Keith ; Cardones, Adela R. ; Finkelstein, Steven E. ; Palmer, Douglas C. ; Antony, Paul A. ; Hwang, Samuel T ; Rosenberg, Steven A. ; Waldmann, Thomas A. ; Restifo, Nicholas P. / Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 27. pp. 9571-9576.
@article{9a65cd12bc0d4ae1b372500fa3f32a35,
title = "Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells",
abstract = "Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.",
keywords = "Homing, IL-15, IL-2, Immunotherapy, Vaccine",
author = "Klebanoff, {Christopher A.} and Luca Gattinoni and Parizad Torabi-Parizi and Keith Kerstann and Cardones, {Adela R.} and Finkelstein, {Steven E.} and Palmer, {Douglas C.} and Antony, {Paul A.} and Hwang, {Samuel T} and Rosenberg, {Steven A.} and Waldmann, {Thomas A.} and Restifo, {Nicholas P.}",
year = "2005",
month = "7",
day = "5",
doi = "10.1073/pnas.0503726102",
language = "English (US)",
volume = "102",
pages = "9571--9576",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "27",

}

TY - JOUR

T1 - Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

AU - Klebanoff, Christopher A.

AU - Gattinoni, Luca

AU - Torabi-Parizi, Parizad

AU - Kerstann, Keith

AU - Cardones, Adela R.

AU - Finkelstein, Steven E.

AU - Palmer, Douglas C.

AU - Antony, Paul A.

AU - Hwang, Samuel T

AU - Rosenberg, Steven A.

AU - Waldmann, Thomas A.

AU - Restifo, Nicholas P.

PY - 2005/7/5

Y1 - 2005/7/5

N2 - Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.

AB - Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.

KW - Homing

KW - IL-15

KW - IL-2

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=22144437688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144437688&partnerID=8YFLogxK

U2 - 10.1073/pnas.0503726102

DO - 10.1073/pnas.0503726102

M3 - Article

C2 - 15980149

AN - SCOPUS:22144437688

VL - 102

SP - 9571

EP - 9576

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 27

ER -